RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
…
Rockwood Research

Corporate filings · Event Monitor · Free for all

← Back

Oric Pharmaceuticals, Inc.

ORIC

Pharmaceutical Preparations · SIC 2834 · CIK 0001796280

SHARE:XLINKEDINEMAIL
Revenue FY2025
—
Net Income
$(129.0M)
EPS (Basic)
$-1.47
Net Margin
—
ROE
-33.7%
Total Equity
$384.0M
Shares Out
104M

Oric Pharmaceuticals, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2018–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Revenue & Net Income (10Y)

Margin Trends

Investor Ownership · 5 funds in our universe

FundPosition Value% of AUMQoQ ChgWeight
Vivo Capital
Vivo Capital
$20.0M
0.3%
—
OrbiMed Advisors
OrbiMed Advisors
$21.8M
0.1%
(25.2%)
Royce & Associates
Royce & Associates
$10.6M
0.1%
(18.8%)
Viking Global Investors
Andreas Halvorsen
$55.5M
0.1%
(12.0%)
Adage Capital Management
Adage Capital Management
$11.4M
0.0%
+205.5%

Insider Transactions

Reading stored insider transactions…